Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Overall survival with pembrolizumab for MCC <br />
Presented By Paul Nghiem at 2018 ASCO Annual Meeting
Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Durable response on anti-PD-1/PD-L1 ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Which patterns of resistance do we see ?
Presented By Selma Ugurel at 2018 ASCO Annual Meeting
Radiologic tumor response to pembrolizumab in patients<br />per viral status<br /><br /><br />
Presented By Paul Nghiem at 2018 ASCO Annual Meeting
Related Documents
